ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc.verified

ALXO

Price:

$1.8

Market Cap:

$94.94M

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers way...[Read more]

Industry

Biotechnology

IPO Date

2020-07-17

Stock Exchange

NASDAQ

Ticker

ALXO

The PE Ratio as of December 2024 (TTM) for ALX Oncology Holdings Inc. (ALXO) is -0.61

According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.61. This represents a change of -77.07% compared to the average of -2.66 of the last 4 quarters.

ALX Oncology Holdings Inc. (ALXO) Historical PE Ratio (quarterly & annually)

How has ALXO PE Ratio performed in the past?

The mean historical PE Ratio of ALX Oncology Holdings Inc. over the last ten years is -33.00. The current -0.61 PE Ratio has changed 84.84% with respect to the historical average. Over the past ten years (40 quarters), ALXO's PE Ratio was at its highest in in the September 2024 quarter at -0.78. The PE Ratio was at its lowest in in the September 2019 quarter at -54.09.

Quarterly (TTM)
Annual

Average

-33.00

Median

-29.17

Minimum

-75.09

Maximum

-3.71

ALX Oncology Holdings Inc. (ALXO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of ALX Oncology Holdings Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 32.01%

Maximum Annual PE Ratio = -3.71

Minimum Annual Increase = -86.18%

Minimum Annual PE Ratio = -75.09

Quarterly (TTM)
Annual
YearPE RatioChange
2023-3.987.16%
2022-3.71-64.21%
2021-10.38-86.18%
2020-75.0932.01%
2019-56.8818.60%

ALX Oncology Holdings Inc. (ALXO) Average PE Ratio

How has ALXO PE Ratio performed in the past?

The current PE Ratio of ALX Oncology Holdings Inc. (ALXO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.02

5-year avg

-30.01

10-year avg

-33.00

ALX Oncology Holdings Inc. (ALXO) PE Ratio vs. Peers

How is ALXO’s PE Ratio compared to its peers?

ALX Oncology Holdings Inc.’s PE Ratio is greater than Cabaletta Bio, Inc. (-1.06), less than Viracta Therapeutics, Inc. (-0.22), greater than EyePoint Pharmaceuticals, Inc. (-3.82), greater than Biomea Fusion, Inc. (-1.03), greater than Crinetics Pharmaceuticals, Inc. (-15.56), greater than Immatics N.V. (-11.82), less than BioAtla, Inc. (-0.37), greater than Aerovate Therapeutics, Inc. (-0.88), greater than Dyne Therapeutics, Inc. (-8.22), greater than Edgewise Therapeutics, Inc. (-22.49), greater than Cullinan Oncology, Inc. (-4.91), greater than Stoke Therapeutics, Inc. (-6.06), greater than Mineralys Therapeutics, Inc. (-4.12), greater than Century Therapeutics, Inc. (-0.64), greater than C4 Therapeutics, Inc. (-2.51), less than TCR2 Therapeutics Inc. (-0.38), greater than Revolution Medicines, Inc. (-12.96), greater than Black Diamond Therapeutics, Inc. (-1.67), less than Atreca, Inc. (-0.06), less than Passage Bio, Inc. (-0.59),

Build a custom stock screener for ALX Oncology Holdings Inc. (ALXO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ALX Oncology Holdings Inc. (ALXO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is ALX Oncology Holdings Inc.'s PE Ratio?

How is the PE Ratio calculated for ALX Oncology Holdings Inc. (ALXO)?

What is the highest PE Ratio for ALX Oncology Holdings Inc. (ALXO)?

What is the 3-year average PE Ratio for ALX Oncology Holdings Inc. (ALXO)?

What is the 5-year average PE Ratio for ALX Oncology Holdings Inc. (ALXO)?

How does the current PE Ratio for ALX Oncology Holdings Inc. (ALXO) compare to its historical average?